[{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Aegis Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Hypersomnia Foundation","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Hypersomnia Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Hypersomnia Foundation"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"RARE-X","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ RARE-X","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ RARE-X"},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Hercules Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Commave Therapeutics"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Gurnet Point Capital"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine\/norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine\/norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Dexmethylphenidate HCl
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
